

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



国药集团  
SINOPHARM

# 國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.\*

*(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)*

**(Stock Code: 01099)**

## ANNOUNCEMENT PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM (CNCM LTD) FOR THE SIX MONTHS ENDED 30 JUNE 2023

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the “**Company**”) dated 23 August 2023 (the “**Announcement**”) in relation to the 2023 interim report of China National Medicines Corporation Ltd. (“**SINOPHARM (CNCM LTD)**”), a subsidiary of the Company and whose A shares are listed on the Shanghai Stock Exchange (stock code: 600511).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited accounting data and financial indicators of SINOPHARM (CNCM LTD) for the six months ended 30 June 2023 (the “**Reporting Period**”) as set out in the Announcement.

*\* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.*

**PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM (CNCMLTD)**

*Unit: Yuan  
Currency: RMB*

	<b>At the end of the Reporting Period</b>	<b>At the end of last year</b>	<b>Changes of this period-end over the end of last year</b>
Total assets	30,839,517,312.09	29,609,041,999.59	4.16%
Net assets attributable to shareholders of the listed company	14,609,775,892.23	14,214,807,659.39	2.78%
	<b>The Reporting Period</b>	<b>Same period of last year</b>	<b>Changes of this period over the same period of last year</b>
Revenue	24,140,175,654.64	22,006,490,053.03	9.70%
Net profit attributable to shareholders of the listed company	984,583,170.50	862,246,884.87	14.19%
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses	951,127,923.58	855,290,137.50	11.21%
Net cash flow arising from operating activities	-166,057,140.22	34,939,821.40	-575.27%
Basic earnings per share (Yuan/Share)	1.3049	1.1428	14.19%
Diluted earnings per share (Yuan/Share)	1.3049	1.1428	14.19%
Basic earnings per share after deducting non-recurring gains and losses (Yuan/Share)	1.2606	1.1336	11.21%
Weighted average return on net assets (%)	6.61	6.61	increased by 0.00 percentage point
Weighted average return on net assets after deducting non-recurring gains and losses (%)	6.38	6.56	decreased by 0.18 percentage point

**INFORMATION ON PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS**

The decrease in net cash flow arising from operating activities was mainly due to the year-on-year decrease in payment from downstream customers during the Reporting Period.

By order of the Board  
**Sinopharm Group Co. Ltd.**  
**Yu Qingming**  
Chairman

Shanghai, the PRC  
23 August 2023

*As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Hu Jianwei, Mr. Ma Ping, Mr. Deng Jindong, Mr. Wang Kan, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao.*